Oncternal Therapeutics ONCT shares are trading higher on Tuesday after the company announced it received a pediatric disease designation from the FDA for its TK216 for the treatment of Ewing Sarcoma.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. Its product pipeline includes Cirmtuzumab, TK216, and ROR1 CAR-T.
Oncternal Therapeutics shares traded up 8.38% to $1.94 on Tuesday. The stock has a 52-week high of $6.29 and a 52-week low of $1.67.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
